mRNA IGF1 Therapy for Urinary Trissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lower urinary tract symptoms (LUTS) such as stress urinary incontinence, urge urinary incontinence, and underactive bladder are limited, with no effective and safe pharmaceutical therapies available, and existing methods often have poor compliance and non-reversible consequences.
Innovation Solution
A therapeutic composition comprising mRNA encoding IGF1, which is administered to treat LUTS, promoting urinary tract tissue regeneration and maintaining therapeutic effects for nine days or more by encoding a signal peptide and a growth factor sequence, specifically using a codon-optimized nucleic acid sequence for human IGF1 with a BDNF pre-domain and pro-domain, and without an E-peptide, to induce IGF1 protein expression and secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (surgery, injections, physical therapy) are used for LUTS, then some therapeutic effect is achieved, but compliance is poor and/or non-reversible consequences occur
Solution Approach 1:
The patent replaces mechanical/invasive treatment systems (surgery, injections, physical therapy devices) with a molecular/biochemical system (mRNA therapy). The mRNA encodes IGF1 protein that is delivered systemically or locally, allowing the body's own cellular machinery to produce the therapeutic protein, thereby eliminating compliance issues associated with repeated mechanical interventions while providing sustained regenerative effects on urinary tract tissues.
2Reliability
If invasive procedures (surgery, injection of bulking agents) are used for LUTS, then continence is restored, but non-reversible consequences occur in case of failed procedures
Solution Approach 1:
The mRNA therapy enables the body's own cells to produce IGF1 protein, which then acts as a self-regulating regenerative agent. The endogenous production mechanism allows for natural control of protein levels and duration, avoiding the permanent foreign material implantation associated with bulking agents or mesh surgery. If the therapy is ineffective, the body naturally degrades the mRNA and stops production, avoiding irreversible consequences.
Solution Approach 2:
The patent changes the fundamental parameter of treatment from permanent structural modification (surgery, implants) to temporary molecular intervention (mRNA that degrades after delivering its message). This parameter change allows the therapeutic effect to be transient and reversible, eliminating the risk of permanent harm from failed procedures while still achieving the desired restoration of continence through regulated protein expression.
3Adaptability or versatility
If no pharmaceutical therapy is available for LUTS, then existing treatment options are limited, but this creates high unmet medical need
Solution Approach 1:
The patent introduces a completely new class of pharmaceutical therapy (mRNA-based protein replacement therapy) for LUTS, substituting the limited mechanical and behavioral treatments with a molecular approach. The mRNA encodes IGF1, a growth factor that promotes tissue regeneration and repair in the urinary tract, providing a versatile and adaptable treatment mechanism that can address various forms of LUTS through a single platform technology with high efficacy potential.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mRNA composition effectively treats LUTS by promoting sustained muscle functional improvement and tissue regeneration, as evidenced by increased urinary bladder leak point pressure and histological preservation of muscle layers, differing from conventional treatments like duloxetine, with a regenerative mechanism that maintains therapeutic effects for an extended period.
Implementation Method 1
mRNA encoding IGF1... to induce IGF1 protein expression and secretion
Data Source
AI summary
The present invention relates to a mRNA and a therapeutic composition thereof for use in a method of treating lower urinary tract symptoms.